Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticum

1990 ◽  
Vol 9 (11) ◽  
pp. 838-841 ◽  
Author(s):  
H. Renaudin ◽  
C. Bébéar
Keyword(s):  
Mycoplasma Hominis ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Andureaplasma Urealyticum

scholarly journals In Vitro Activity of a New Quinoline Derivative, ER-2, against Clinical Isolates of Mycoplasma pneumoniae and Mycoplasma hominis

2009 ◽  
Vol 53 (12) ◽  
pp. 5317-5318 ◽  
Author(s):  
Shilpakala Sainath Rao ◽  
Raghavachari Raghunathan ◽  
Malathi Raghunathan ◽  
Ramesh Ekambaram
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Mycoplasma Hominis ◽  
Quinoline Derivative ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

2008 ◽  
Vol 52 (10) ◽  
pp. 3776-3778 ◽  
Author(s):  
Ken B. Waites ◽  
Donna M. Crabb ◽  
Lynn B. Duffy
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Antimicrobial Agents ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
The Other ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Mycoplasma Fermentans

ABSTRACT The in vitro susceptibilities of 151 unique clinical isolates of Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, Mycoplasma genitalium, and Ureaplasma species to DC-159a, an investigational fluoroquinolone, in comparison with those to other agents were determined. Macrolides were the most active agents against M. pneumoniae and M. genitalium, whereas clindamycin was most active against M. hominis. DC-159a MICs were ≤0.5 μg/ml for all Mycoplasma species and ≤4 μg/ml for ureaplasmas. DC-159a was the most active fluoroquinolone tested against M. pneumoniae and M. fermentans, and it was second to moxifloxacin against the other species. It was bactericidal against 10 M. pneumoniae isolates and demonstrated killing of ≥99.9% of the inoculum at 24 h for 2 isolates. The excellent in vitro activity of DC-159a demonstrates its potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

scholarly journals In Vitro Activity of Trovafloxacin Compared to Those of Five Antimicrobials against Mycoplasmas IncludingMycoplasma hominis and Ureaplasma urealyticumFluoroquinolone-Resistant Isolates That Have Been Genetically Characterized

2000 ◽  
Vol 44 (9) ◽  
pp. 2557-2560 ◽  
Author(s):  
C. M. Bebear ◽  
H. Renaudin ◽  
A. Charron ◽  
D. Gruson ◽  
M. Lefrancois ◽  
...  
Keyword(s):  
Ureaplasma Urealyticum ◽  
Mycoplasma Hominis ◽  
The Other ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Resistant Species

ABSTRACT The in vitro activity of trovafloxacin against 125 strains ofMycoplasma species and Ureaplasma urealyticum, including fluoroquinolone-susceptible and fluoroquinolone-resistant species, was compared to those of other fluoroquinolones, doxycycline, and erythromycin. The MIC at which 90% of isolates are inhibited for all fluoroquinolone-susceptible strains was 0.25 μg/ml. Whatever the associated mutations, trovafloxacin exhibited greater activity than the other fluoroquinolones tested against fluoroquinolone-resistantMycoplasma hominis and U. urealyticum isolates.

Sign in / Sign up

Export Citation Format

Share Document